The US Food and Drug Administration has approved a new indication for the ulcerative colitis drug, Lialda (mesalamine), for the maintenance of remission in patients with the disease, according to the drug’s sponsor, Shire Plc. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
